Publisher's Synopsis
Recombinant DNA (rDNA) molecules are DNA molecules formed by laboratory methods of genetic recombination (such as molecular cloning) to bring together genetic material from multiple sources, creating sequences that would not otherwise be found in the genome. Recombinant DNA is possible because DNA molecules from all organisms share the same chemical structure. They differ only in the nucleotide sequence within that identical overall structure. There are three different methods by which Recombinant DNA is made. They are Transformation, Phage Introduction, and Non-Bacterial Transformation. This book, Recombinant DNA and Biotechnology, emphasizes major techniques of product development and manufacturing in biotechnology are discussed, with a focus on recombinant DNA technology. For recombinant-DNA technology, the issues of gene isolation, gene cloning, protein expression, scale-up (manufacturing), and quality assurance are addressed. First chapter focuses on recombinant DNA technology in emerging modalities for melanoma immunotherapy. Second chapter gives an approach on genetic engineering and biotechnology of growth hormones. In third chapter, we provide an overview of how wtAAV and rAAV alter the fate of the host cells through DDR, and how DDR processes the viral genomic DNA by exerting DNA repair machinery to establish the lytic and latent life cycles of wtAAV and transduction of rAAV. Fourth chapter mainly focuses on the XP syndrome, deficiencies in NER can also lead to other genetic diseases, such as trichothiodystrophy (TTD), Cockayne syndrome (CS), cerebro-oculo- facial-skeletal syndrome (COFS) and UV-sensitive syndrome (UVsS), all of which have photosensitivity as a common feature. Fifth chapter overviews on recombinant antibodies and nonantibody scaffolds for immunoassays. Immunoassays are frequently applied to the analysis of both low molecular ligands and macromolecular drugs, and are also applied in such important areas as the quantitation of biomarkers that indicate disease progression and immunogenicity of therapeutic drug candidates. A new building-brick-style parallel DNA assembly framework for simple and flexible batch construction is presented in sixth chapter. In seventh chapter, we examined the roles of two PHF8 homologs, JMJD-1.1 and JMJD-1.2, in the model organism C. elegans in response to DNA damage. In eighth chapter, we report the production of large amounts of soluble and pure recombinant human PBX1:PREP1 complex in an active form capable of binding DNA. In ninth chapter, we provide evidence that retinal pigment epithelium (RPE) cells lacking ATR have decreased density with abnormal morphology, a decreased frequency of HR and an increased level of chromosomal damage. Last chapter focuses on diversity and recombination of dispersed ribosomal DNA and protein coding genes in microsporidia. recombinant antibodies and non-antibody scaffolds for immunoassays.
